MICs and minimum fungicidal concentrations of amphotericin B, miconazole, itraconazole, ketoconazole, fluconazole, and flucytosine against 17 isolates of Scopulariopsis spp. were determined by a broth microdilution method. All the isolates were resistant to itraconazole, fluconazole, and flucytosine, and amphotericin B, miconazole, and ketoconazole MICs were low for only a few.
amphotericin B, miconazole, itraconazole, and ketoconazole; 0.125 to 64 g/ml for fluconazole; and 0.25 to 128 g/ml for flucytosine. The temperature of incubation was of 30°C, and MIC readings were made after 48 and 72 h. The amphotericin B MIC was defined as the lowest drug concentration with which there was a complete absence of growth. MICs of the azoles and flucytosine were defined as the lowest drug concentration that gave only slight growth, corresponding to approximately 25% of the growth of the control. The minimum fungicidal concentrations (MFC) were obtained by placing 10 l from each well which showed inhibition onto oatmeal plates. Fungal colonies were counted after incubation for 48 h at 30°C. The MFC was defined as the lowest drug concentration at which one colony or less was visible on the agar plate. To compare the MIC readings at 48 and 72 h, differences of no more than 1 dilution (one well) were used to calculate the percentage of agreement. The kappa test was used to calculate the degree of agreement. A kappa value () greater than 0.75 was taken to represent excellent agreement, values below 0.40 were taken to represent poor agreement, and values between 0.40 and 0.75 were taken to represent fair to good agreement. Table 1 shows that only some of the strains, belonging to different species, displayed moderate susceptibility to amphotericin B, miconazole, and ketoconazole. All of them were clearly resistant to itraconazole, fluconazole, and flucytosine. S. carbonaria was the species for which MICs and MFCs were generally the lowest. S. brevicaulis showed very variable results. Amphotericin B MICs were relatively low for two of the five isolates, miconazole MICs were low for three, and ketoconazole MICs were low for four, although MICs were not lower than 1 g/ml in any case. The MIC ranges were generally wider and lower than the ranges of the MFCs. Excellent agreement between the MICs at 48 and 72 h was shown for itraconazole ( ϭ 1), fluconazole ( ϭ 1), flucytosine ( ϭ 1), and miconazole ( ϭ 0.76). Good agreement was shown for ketoconazole ( ϭ 0.64), and poor agreement was shown for amphotericin B ( ϭ 0.28).
Although amphotericin B is the drug most frequently used, the correct treatment for invasive Scopulariopsis infections is still unclear. The success rate of this drug is only about 40%. On six occasions amphotericin B was used alone (11, 12, 15, 17, 22, 23) , but on only three of them did the patients make good progress. One patient was first treated with different doses of amphotericin B without success, but the change to a liposomal preparation of the same polyene compound resolved the infection (10) . In another five patients, amphotericin B was used in combination with other antifungal drugs (ketoconazole for one patient, miconazole for another, and itraconazole for another three) (4, 9, 15, 16, 19) . Combined with itraconazole, amphotericin B showed good results on three occasions. Itraconazole was also used alone for one patient with ulcerous cheilitis (1) and one with plantar infection (5). The first patient relapsed after a certain degree of improvement, but the second was cured completely after the failure of ketoconazole and fluconazole. Ketoconazole was effective for the treatment of psoriasiform plaques in a patient with human immunodeficiency virus (6) , and miconazole cured a mycotic corneal ulcer which had developed after herpetic keratitis (2). Flucytosine was used for only one patient with mycetoma, in whom it was not effective (3).
Results obtained by authors who have tested the in vitro antifungal susceptibilities of Scopulariopsis spp. are generally contradictory, probably due to the variety of methods used. However, in only six articles were there details of the method employed (5, 9, 11, 14, 20, 21) . In four of the studies the agar dilution method was used, a disc diffusion method was used in another, and a broth dilution method was used in the sixth. Regli et al. (20) carried out the widest study, testing 38 strains of S. brevicaulis against 10 antifungal drugs. They compared three solid media (Sabouraud dextrose agar, yeast malt agar, and Casitone agar) and concluded that S. brevicaulis was highly resistant to griseofulvine, tolnaftate, amphotericin B, and flucytosine and moderately sensitive to miconazole and ketoconazole. More data about the in vitro antifungal susceptibilities of clinical isolates of Scopulariopsis have appeared in some reports of human infections caused by these fungi (1, 2, 4, 5, 9, 11, 13, 14, 21). Amphotericin B was defined as ineffective every time it was tested (seven times). MICs of fluconazole and flucytosine were low for only one of four and one of six isolates, respectively. Miconazole and ketoconazole showed high MICs for half of the assayed isolates (2 of 4 in each case). Itraconazole, being active in three of the five tests, was the antifungal drug that showed the lowest MIC in these clinical reports, and another isolate was defined as relatively sensitive. This contrasts with our results, where itraconazole MICs for none of the 17 strains could be considered as indicating activity.
In general, our data confirm the high in vitro resistance of Scopulariopsis spp. reported by other authors. More data are needed to draw more valid conclusions about the susceptibility of Scopulariopsis both in vitro and in vivo and to determine whether in vitro testing is more reliable with conidia than with hyphae (8) . Every clinical case report would therefore need to include data on in vitro antifungal susceptibility testing, in which the method used, the MICs, the treatment, and the clinical outcome would be described in detail. However, the data available make us pessimistic about an effective treatment for these infections, although the relative success shown by itraconazole in some clinical cases merits special attention. Experimental studies to test the effectiveness of this drug alone and/or in combination with others are required to confirm the sparse clinical data that exist. The finding of new compounds active against this refractory fungus constitutes a priority challenge to modern medicine. 
